Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. González-Martín A, et al. Among authors: moore rg. Eur J Cancer. 2023 Aug;189:112908. doi: 10.1016/j.ejca.2023.04.024. Epub 2023 May 3. Eur J Cancer. 2023. PMID: 37263896 Free article. Clinical Trial.
Luteoma of pregnancy masquerading as a granulosa cell tumor.
Zhang N, Thappa S, Navarro Sanchez J, Smith A, Liu C, Angel C, DuBeshter B, Morrison J, Pressman E, Moore R. Zhang N, et al. Gynecol Oncol Rep. 2023 Mar 17;46:101163. doi: 10.1016/j.gore.2023.101163. eCollection 2023 Apr. Gynecol Oncol Rep. 2023. PMID: 37082520 Free PMC article.
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Valabrega G, Pothuri B, Oaknin A, Graybill WS, Sánchez AB, McCormick C, Baurain JF, Tinker AV, Denys H, O'Cearbhaill RE, Hietanen S, Moore RG, Knudsen AØ, de La Motte Rouge T, Heitz F, Levy T, York W, Gupta D, Monk BJ, González-Martín A. Valabrega G, et al. Among authors: moore rg. Gynecol Oncol. 2024 Jun 3;187:128-138. doi: 10.1016/j.ygyno.2024.03.009. Online ahead of print. Gynecol Oncol. 2024. PMID: 38833992
Interfacially Enhanced Superconductivity in Fe(Te,Se)/Bi4Te3 Heterostructures.
Chen AH, Lu Q, Hershkovitz E, Crespillo ML, Mazza AR, Smith T, Ward TZ, Eres G, Gandhi S, Mahfuz MM, Starchenko V, Hattar K, Lee JS, Kim H, Moore RG, Brahlek M. Chen AH, et al. Among authors: moore rg. Adv Mater. 2024 May 8:e2401809. doi: 10.1002/adma.202401809. Online ahead of print. Adv Mater. 2024. PMID: 38717569
A whole food, plant-based randomized controlled trial in metastatic breast cancer: feasibility, nutrient, and patient-reported outcomes.
Campbell EK, Campbell TM, Culakova E, Blanchard L, Wixom N, Guido JJ, Fetten J, Huston A, Shayne M, Janelsins MC, Mustian KM, Moore RG, Peppone LJ. Campbell EK, et al. Among authors: moore rg. Breast Cancer Res Treat. 2024 Mar 30. doi: 10.1007/s10549-024-07284-z. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38553649
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. González-Martín A, et al. Among authors: moore rg. Future Oncol. 2024 Mar 19. doi: 10.2217/fon-2023-0782. Online ahead of print. Future Oncol. 2024. PMID: 38501262 Review.
269 results